775 results on '"Pilewski, Joseph M."'
Search Results
2. Effect of elexacaftor/tezacaftor/ivacaftor on mucus and mucociliary clearance in cystic fibrosis
3. Type‐1 immunity and endogenous immune regulators predominate in the airway transcriptome during chronic lung allograft dysfunction
4. Systems serology in cystic fibrosis: Anti-Pseudomonas IgG1 responses and reduced lung function
5. Advancing the pipeline of cystic fibrosis clinical trials: a new roadmap with a global trial network perspective
6. Lung transplant recipients with telomere-mediated pulmonary fibrosis have increased risk for hematologic complications
7. Position paper: Models of post-transplant care for individuals with cystic fibrosis
8. Rabbit Antithymocyte Globulin for Treatment of Corticosteroid Refractory Acute Cellular Rejection After Lung Transplantation
9. Pseudomonas aeruginosa utilizes host polyunsaturated phosphatidylethanolamines to trigger theft-ferroptosis in bronchial epithelium
10. Use of elexacaftor/tezacaftor/ivacaftor among cystic fibrosis lung transplant recipients
11. Elexacaftor-Tezacaftor- Ivacaftor improves sinonasal outcomes in cystic fibrosis
12. Outpatient Pharmacologic Management of Lung Transplant Candidates on the Waiting List
13. Incidence of Acute Cellular Rejection After Granulocyte Colony-Stimulating Factor in Lung Transplant Recipients.
14. The effect of discontinuing hypertonic saline or dornase alfa on mucociliary clearance in elexacaftor/tezacaftor/ivacaftor treated people with cystic fibrosis: The SIMPLIFY-MCC Study
15. Lung Transplantation for Cystic Fibrosis
16. Cystic fibrosis foundation consensus statements for the care of cystic fibrosis lung transplant recipients
17. Long-term safety and efficacy of tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study
18. Challenges in the use of highly effective modulator treatment for cystic fibrosis
19. Donor-specific antibody characteristics, including persistence and complement-binding capacity, increase risk for chronic lung allograft dysfunction
20. Elexacaftor-tezacaftor-ivacaftor decreases pseudomonas abundance in the sinonasal microbiome in cystic fibrosis.
21. Interleukin-22 Inhibits Respiratory Syncytial Virus Production by Blocking Virus-Mediated Subversion of Cellular Autophagy
22. Cystic Fibrosis Foundation consensus guidelines for the care of individuals with advanced cystic fibrosis lung disease
23. Prevalence of unmet palliative care needs in adults with cystic fibrosis
24. Underweight Patients With Cystic Fibrosis Have Acceptable Survival Following Lung Transplantation: A United Network for Organ Sharing Registry Study
25. Routine deep vein thrombosis screening after lung transplantation: Incidence and risk factors
26. Cystic fibrosis: candidate selection and impact of the cystic fibrosis transmembrane conductance regulator therapy
27. A longitudinal analysis of respiratory symptoms in people with cystic fibrosis with advanced lung disease on and off ETI
28. Elexacaftor–tezacaftor–ivacaftor decreases pseudomonas abundance in the sinonasal microbiome in cystic fibrosis
29. Feasibility Testing of a Web-Based Reproductive Decision Support Tool for Cystic Fibrosis
30. Effect of elexacaftor/tezacaftor/ivacaftor on mucus and mucociliary clearance in cystic fibrosis
31. Long-Term Ivacaftor in People Aged 6 Years and Older with Cystic Fibrosis with Ivacaftor-Responsive Mutations
32. Lung transplant referral for individuals with cystic fibrosis: Cystic Fibrosis Foundation consensus guidelines
33. Role of Extracellular Vesicles in the Propagation of Lung Fibrosis in Systemic Sclerosis
34. First Successful Lung Transplantation for Sickle Cell Disease with Severe Pulmonary Arterial Hypertension and Pulmonary Veno‐Occlusive Disease
35. Preoperative Evaluation and Preparation for Lung Transplantation
36. Sexual and reproductive health behaviors and experiences reported by young women with cystic fibrosis
37. Sexual and reproductive health care utilization and preferences reported by young women with cystic fibrosis
38. Gastrin-releasing peptide receptor expression in non-cancerous bronchial epithelia is associated with lung cancer: a case-control study.
39. Provider Attitudes and Practices toward Sexual and Reproductive Health Care for Young Women with Cystic Fibrosis
40. A longitudinal analysis of respiratory symptoms in people with cystic fibrosis with advanced lung disease on and off ETI
41. Comprehensive Gene Expression Profiles Reveal Pathways Related to the Pathogenesis of Chronic Obstructive Pulmonary Disease
42. Embedded Specialist Palliative Care in Cystic Fibrosis: Results of a Randomized Feasibility Clinical Trial
43. Sequential redo-bilateral lung transplantation in recipient with prior heart-lung transplantation with tracheal anastomosis
44. Impact of a Mobile Health Intervention on Long-term Nonadherence After Lung Transplantation: Follow-up After a Randomized Controlled Trial
45. Successful Lung Transplantation in a Patient with Chronic Granulomatous Disease
46. Phage therapy in a lung transplant recipient with cystic fibrosis infected with multidrug‐resistant Burkholderia multivorans
47. First Characterization of the Transcriptome of Lung Fibroblasts of SSc Patients and Healthy Donors of African Ancestry
48. Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: Safety and efficacy in an expanded access program in the United States
49. Optical or Transbronchial Biopsy to Diagnose Acute Cellular Rejection
50. Update on Lung Transplantation for Cystic Fibrosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.